Greg Skalicky
President
Expertise:
As President of EVERSANA, Greg is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Greg understands all facets of the pharmaceutical industry, spanning clinical operations to commercial success. Greg’s previous roles include Chief Enterprise Business Officer and Executive Vice President and General Manager at a global bio-pharmaceutical solutions organization, where he successfully managed business units and teams of several thousand employees. Skalicky holds a Bachelor of Science in Biology from Temple University and a Master of Business Administration from Villanova University. He is an active member across several industry panels and consortiums.
Articles by Greg Skalicky
“Nothing changes if nothing changes.”
Patients deserve quick and easy access to care. That’s why EVERSANA DIRECT goes beyond the “bare minimum” of DTP solutions, delivering a seamless end‑to‑end patient experience—from patient identification through prescription refills. Two-thirds of drug launches fall short of revenue goals, but a new approach is changing the trend. Today’s most successful brands are rethinking the traditional playbook by pairing integrated commercialization models with direct-to-patient (DTP) […]
“Nothing changes if nothing changes.”
“Nothing changes if nothing changes.” Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must. Two-thirds of drug launches fall short of revenue goals, but a new approach is changing the trend. Today’s most successful brands are rethinking the traditional playbook by pairing […]
Optimizing Product Commercialization in Today’s IDN Environment
Traditional sales models that rely solely on prescriber outreach or consumer advertising are no longer effective. With nearly 70% of U.S. physicians employed by Integrated Delivery Networks (IDNs), the way therapies are evaluated, approved, and accessed has fundamentally changed. For life sciences companies, understanding the key stakeholders and decision-making processes within each IDN is critical […]
The End of the Blockbuster: Adapting to a New Pharmaceutical Landscape With a New Commercialization Model
Traditional commercialization strategies that once fueled massive growth and profitability are no longer viable in today’s complex and competitive market. High SG&A costs without resulting revenue, patent cliffs, rising patient acquisition costs, convoluted supply chain management, fragmented execution, lack of pricing transparency, and complicated relationships with PBMs are some of the internal and external pressures […]
Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success
Unlock the Future of Drug Commercialization Discover the Proven Strategies Behind Successful Drug Launches Are you ready to revolutionize your drug commercialization approach? Download our exclusive whitepaper, “Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success,” and gain insights from industry leaders at EVERSANA. What You’ll Learn: Comprehensive Outsourcing Strategies: Explore how EVERSANA COMPLETE Commercialization® offers both […]
The Promise of Direct-to-Patient – What’s Really Needed for Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with delays and outdated workflows. Imagine a world where patients can swiftly access the right specialists, understand complex therapies, and […]
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric”. This comprehensive guide provides insights into: The need for a unified, […]
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Integrated Delivery Networks have impacted everything from drug launches to sales approaches. Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, President at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets. Pharmaceutical Executive: How are IDNs being […]
Bending the “Commercialization Curve” in Large Pharma
If the last few years have taught us anything, it’s that it’s more important than ever to embrace change and new ways to bring therapies to patients. This is especially the case when considering commercialization and globalization in the life sciences and pharmaceutical industries. Although many would agree that this adaptation is important, we […]